New CAR-T therapy targets lymphoma that escapes standard treatment

NCT ID NCT07369492

Recruiting now Disease control Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new type of CAR-T cell therapy called BAFF-R CAR-T for adults with a specific kind of B-cell lymphoma that has stopped responding to treatment and does not have the CD19 marker. The study will enroll 30 people to see if the treatment is safe and tolerable. Participants receive a single infusion of their own modified immune cells designed to find and attack the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAFF-R CAR-T cells
What this could lead to: If this works, it could offer a new treatment option for people with B-cell lymphoma that does not respond to standard therapies and has stopped responding to CD19-targeted treatments.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so it is too soon to know if it is safe or effective. CAR-T cell therapy can cause serious side effects like cytokine release syndrome and nervous system problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA

Contacts and locations

Locations

Suzhou Hongci Hematology Hospital
RECRUITING

Suzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.